No annual revenue total was found in Adicet Bio, Inc.'s SEC filings.
Adicet Bio, Inc. (ACET) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$97.0 million. As of Jun 30, 2026 it held $118.2 million in cash and investments and $12.9 million in total debt.
Revenue
—
Net income (TTM)
$-98.97M
+16.6% vs year-ago TTM
Operating cash flow (TTM)
$-84.53M
+13.9% vs year-ago TTM
Free cash flow (TTM)
$-84.97M
+15.2% vs year-ago TTM
EPS (TTM)
$-10.55
-401.1% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
9.35M
-2.6% vs prior year
Net cash
$105.34M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACET (Nasdaq)
- Fiscal year ends
- December 26
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720580
- Former names
- resTORbio, Inc. (until Aug 21, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M |
| Diluted EPS | -$16.95 | -$21.33 | -$3.31 | -$1.70 | — |
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
| Stockholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M |
| Cash and investments | $158.5M | $176.3M | $159.7M | $257.7M | $277.5M |
| Total debt | $14.7M | $17.2M | $20.9M | $21.0M | $20.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 680 Adicet Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.